Duloxetine for Chronic Pain
For chronic musculoskeletal or neuropathic pain in adults, start duloxetine at 30 mg once daily for 1 week, then increase to the target dose of 60 mg once daily—doses above 60 mg provide no additional benefit and only increase adverse effects. 1
Dosing Regimen
Initial Dosing
- Start: 30 mg once daily for 1 week to allow patients to adjust and minimize nausea 2, 1
- Target dose: 60 mg once daily after the first week 1
Maximum Dosing
- Do not exceed 60 mg once daily for chronic pain conditions 1
- Evidence consistently shows that 120 mg daily provides no additional efficacy compared to 60 mg, but significantly increases adverse effects and discontinuation rates 1, 3
- In clinical trials, patients who failed to respond to 60 mg daily showed no improvement when blindly titrated to 120 mg 1
Duration of Adequate Trial
- Allow 4 weeks at target dose to assess efficacy 2
- Pain reduction may begin as early as week 1 in some patients 1
Evidence for Specific Pain Conditions
Neuropathic Pain
Duloxetine is a first-line medication for neuropathic pain, particularly diabetic peripheral neuropathy (DPN). 2
- Diabetic peripheral neuropathy: Consistent efficacy demonstrated with 60 mg once daily, with response rates (≥50% pain reduction) of 57-68% vs 35-47% for placebo 3, 4
- Other neuropathic pain: Evidence is limited—duloxetine has not been adequately studied in conditions beyond DPN, so efficacy in other neuropathic pain syndromes remains uncertain 2
Chronic Musculoskeletal Pain
Duloxetine 60 mg once daily is effective for chronic musculoskeletal pain, including chronic low back pain, osteoarthritis, and fibromyalgia. 1, 5
- Chronic low back pain: Demonstrated significant pain reduction compared to placebo in multiple trials 1, 6
- Osteoarthritis pain: Significant improvement in pain severity and physical function 7
- Fibromyalgia: Effective at 60 mg daily with NNTB of 8, though benefit may be greater in patients with comorbid depression 3, 6
Safety Considerations and Adverse Effects
Common Adverse Effects
- Nausea is the most common adverse effect—mitigated by starting at 30 mg daily for 1 week 2, 3
- Other frequent effects: somnolence, headache, constipation, hyperhidrosis, fatigue 3, 4, 7
- Discontinuation due to adverse events: 4.3-14.9% in clinical trials 4
Cardiovascular Safety
- No clinically significant ECG or blood pressure changes at therapeutic doses 2
- Safer cardiovascular profile than tricyclic antidepressants 2, 8
Hepatic Monitoring
- Aminotransferase monitoring is unnecessary in routine practice 2
- Avoid use in patients with chronic liver disease or cirrhosis 1
Renal Considerations
- Avoid in severe renal impairment (GFR <30 mL/min) 1
- Use lower starting doses and gradual titration in patients with diabetes-related renal disease 1
Discontinuation
- Always taper gradually rather than stopping abruptly to minimize discontinuation syndrome 1
- Withdrawal symptoms include: dizziness, headache, nausea, paresthesia, irritability, insomnia 1
Drug Interactions
- Contraindicated with MAOIs: Allow 14 days after stopping MAOI before starting duloxetine; allow 5 days after stopping duloxetine before starting MAOI 1
- Avoid concurrent use with linezolid or IV methylene blue due to serotonin syndrome risk 1
Treatment Algorithm
Step 1: Patient Selection
- Confirm chronic pain diagnosis (neuropathic or musculoskeletal)
- Screen for contraindications: severe renal impairment (GFR <30), chronic liver disease, current MAOI use
- Assess for comorbid depression or anxiety (may enhance benefit) 2, 3
Step 2: Initiation
- Start 30 mg once daily for 1 week
- Educate patient about nausea (typically transient) and need for gradual titration
Step 3: Titration
- Increase to 60 mg once daily after week 1
- Continue for minimum 4 weeks at target dose
Step 4: Response Assessment
- Substantial relief (pain reduced to ≤3/10): Continue treatment 2
- Partial relief (pain ≥4/10): Add another first-line medication (gabapentinoid or TCA) rather than increasing duloxetine dose 2
- Inadequate relief (<30% reduction): Switch to alternative first-line medication 2
Step 5: Long-Term Management
- Periodically reassess need for continued treatment 1
- If discontinuing, taper gradually over several weeks 1
Critical Pitfalls to Avoid
Do not escalate beyond 60 mg daily—this is the most common error, as higher doses only increase side effects without improving efficacy 1
Do not skip the 30 mg starting dose—jumping directly to 60 mg significantly increases nausea and early discontinuation 2
Do not expect universal efficacy in all neuropathic pain—evidence is strong only for diabetic peripheral neuropathy 2
Do not abruptly discontinue—always taper to avoid withdrawal syndrome 1
Do not overlook renal function in diabetic patients—adjust dosing or avoid use if GFR <30 mL/min 1